PET evaluation of fatty tumors in the extremity: Possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma

ObjectiveThe relative utility of various preoperative diagnostic imaging modalities, including PET (utilizing FDG and FMT), CT, and MR imaging, for evaluation of lipoma and liposarcoma, especially well-differentiated liposarcoma, was investigated.MethodsImaging findings in 32 patients with histopathologically documented lipoma, including one with fibrolipoma and one with angiolipoma, and 25 patients with liposarcomas whose subtypes included 10 well-differentiated, 10 myxoid, and 5 other types were reviewed retrospectively. Pre-operative imaging included FDG-PET (n = 44), FMT-PET (n = 21), CT (n = 25), and MR imaging (n = 53).ResultsStatistically significant imaging features of MR images favoring a diagnosis of liposarcoma involved lesions containing less than 75% fat (p < 0.001) as well as the presence of septa (p < 0.001). As compared with well-differentiated liposarcoma, benign lesions were differentiated significantly only by the presence of septa (p < 0.001), which also provided significant differentiation on CT (p < 0.05). The mean SUVs for malignant tumors were significantly higher than those for benign lesions in both FDG- and FMT-PET analyses (p < 0.0001, p = 0.0011, respectively). By using a cut-off value for FDG- and FMT-PET set at 0.81 and 1.0 respectively, which provided the highest accuracy, benign lesions were differentiated significantly from liposarcomas (p < 0.001, and p < 0.02). Furthermore, benign tumors and the three subtypes of liposarcoma were divided significantly into four biological grades by FDG- and FMT-accumulation rates (rho = 0.793, p < 0.0001; and rho = 0.745, p = 0.0009, respectively). A cut-off value of 0.81 for FDG-PET provided significant differentiation between benign lesions and well-differentiated liposarcoma (p < 0.01).ConclusionsThe presence of septa on MR images differentiated lipomas from liposarcoma, even well-differentiated type. PET analysis, especially FDG-PET, quantitatively provided not only the differentiation but also the metabolic separation among subtypes of liposarcoma. Interpretation of the visual diagnostic modalities requires extensive experience and carries a risk of ignoring a critical portion of malignancy. PET metabolic imaging may be an objective and useful modality for evaluating adipose tissue tumors preoperatively.

[1]  J. V. van Horn,et al.  Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  K. Takagishi,et al.  Carbon-11 Choline Positron Emission Tomography in Musculoskeletal Tumors: Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography , 2003, Journal of computer assisted tomography.

[3]  M. J. Fusselman,et al.  Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. , 1996, Radiology.

[4]  K. Takagishi,et al.  Schwannoma of the extremities: the role of PET in preoperative planning , 2001, European Journal of Nuclear Medicine.

[5]  R P Williams,et al.  Noninvasive grading of musculoskeletal tumors using PET. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Tomio Inoue,et al.  FDG-PET in differential diagnosis and grading of chondrosarcomas. , 1999, Journal of computer assisted tomography.

[7]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[8]  Tomio Inoue,et al.  PET imaging of musculoskeletal tumours with fluorine-18 α-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET , 2000, European Journal of Nuclear Medicine.

[9]  L. Griffeth,et al.  PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. , 1992, Radiology.

[10]  B. Shmookler,et al.  Liposarcoma of the extremities: MR and CT findings in the histologic subtypes. , 1993, Radiology.

[11]  Laura W Bancroft,et al.  Imaging of fatty tumors: distinction of lipoma and well-differentiated liposarcoma. , 2002, Radiology.

[12]  M. Enjoji,et al.  Liposarcoma. A clinicopathologic subtyping of 52 cases. , 1982, Acta pathologica japonica.

[13]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[14]  P. Munk,et al.  Lipoma and liposarcoma: evaluation using CT and MR imaging. , 1997, AJR. American journal of roentgenology.

[15]  Kazuhisa Hatayama,et al.  Evaluation of Hemangioma by Positron Emission Tomography: Role in a Multimodality Approach , 2003, Journal of computer assisted tomography.

[16]  W Vaalburg,et al.  Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  H. Hatano,et al.  Treatment of myxoid liposarcoma by marginal or intralesional resection combined with radiotherapy. , 2003, Anticancer research.

[18]  K. Takagishi,et al.  Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning , 2000 .

[19]  S. Weiss Lipomatous tumors. , 1996, Monographs in pathology.

[20]  S. Larson,et al.  Metabolic imaging of human extremity musculoskeletal tumors by PET. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  H. Einarsdottir,et al.  110 Subfascial Lipomatous Tumors , 1999, Acta radiologica.